134 related articles for article (PubMed ID: 37204046)
1. Exploiting Cancer Vulnerabilities by Blocking of the DHODH and GPX4 Pathways: A Multifunctional Bodipy/PROTAC Nanoplatform for the Efficient Synergistic Ferroptosis Therapy.
Yao L; Yang N; Zhou W; Akhtar MH; Zhou W; Liu C; Song S; Li Y; Han W; Yu C
Adv Healthc Mater; 2023 Oct; 12(26):e2300871. PubMed ID: 37204046
[TBL] [Abstract][Full Text] [Related]
2. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Mao C; Liu X; Zhang Y; Lei G; Yan Y; Lee H; Koppula P; Wu S; Zhuang L; Fang B; Poyurovsky MV; Olszewski K; Gan B
Nature; 2021 May; 593(7860):586-590. PubMed ID: 33981038
[TBL] [Abstract][Full Text] [Related]
3. A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract][Full Text] [Related]
4. The Warburg effect modulates DHODH role in ferroptosis: a review.
Amos A; Amos A; Wu L; Xia H
Cell Commun Signal; 2023 May; 21(1):100. PubMed ID: 37147673
[TBL] [Abstract][Full Text] [Related]
5. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer.
Zhou TJ; Zhang MM; Liu DM; Huang LL; Yu HQ; Wang Y; Xing L; Jiang HL
Biomaterials; 2024 Mar; 305():122447. PubMed ID: 38154441
[TBL] [Abstract][Full Text] [Related]
6. Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.
Wang C; Zheng C; Wang H; Shui S; Jin H; Liu G; Xu F; Liu Z; Zhang L; Sun D; Xu P
Eur J Med Chem; 2023 Feb; 247():115072. PubMed ID: 36603510
[TBL] [Abstract][Full Text] [Related]
7. Manganese induces tumor cell ferroptosis through type-I IFN dependent inhibition of mitochondrial dihydroorotate dehydrogenase.
Zhang S; Kang L; Dai X; Chen J; Chen Z; Wang M; Jiang H; Wang X; Bu S; Liu X; Zhang G; Tang H
Free Radic Biol Med; 2022 Nov; 193(Pt 1):202-212. PubMed ID: 36228830
[TBL] [Abstract][Full Text] [Related]
8. DHODH tangoing with GPX4 on the ferroptotic stage.
Wang F; Min J
Signal Transduct Target Ther; 2021 Jun; 6(1):244. PubMed ID: 34145214
[No Abstract] [Full Text] [Related]
9. Mitochondria-Targeted Prodrug Nanoassemblies for Efficient Ferroptosis-Based Therapy via Devastating Ferroptosis Defense Systems.
Liu N; Lin Q; Huang Z; Liu C; Qin J; Yu Y; Chen W; Zhang J; Jiang M; Gao X; Huo S; Zhu X
ACS Nano; 2024 Mar; 18(11):7945-7958. PubMed ID: 38452275
[TBL] [Abstract][Full Text] [Related]
10. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression.
Hai Y; Fan R; Zhao T; Lin R; Zhuang J; Deng A; Meng S; Hou Z; Wei G
Pharmacol Res; 2024 Apr; 202():107115. PubMed ID: 38423231
[TBL] [Abstract][Full Text] [Related]
11. Depletion of SOD2 enhances nasopharyngeal carcinoma cell radiosensitivity via ferroptosis induction modulated by DHODH inhibition.
Amos A; Jiang N; Zong D; Gu J; Zhou J; Yin L; He X; Xu Y; Wu L
BMC Cancer; 2023 Feb; 23(1):117. PubMed ID: 36737723
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Functional Nanomedicine Enhances Ferroptosis Therapy for Breast Tumors by a Blocking Defensive Redox System.
Chen S; Yang J; Liang Z; Li Z; Xiong W; Fan Q; Shen Z; Liu J; Xu Y
ACS Appl Mater Interfaces; 2023 Jan; 15(2):2705-2713. PubMed ID: 36622364
[TBL] [Abstract][Full Text] [Related]
13. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience.
Lee J; Roh JL
Cancer Lett; 2023 Apr; 559():216119. PubMed ID: 36893895
[TBL] [Abstract][Full Text] [Related]
14. Dihydroorotate dehydrogenase promotes cell proliferation and suppresses cell death in esophageal squamous cell carcinoma and colorectal carcinoma.
Shi ZZ; Jin X; Li WT; Tao H; Song SJ; Fan ZW; Jiang W; Liang JW; Bai J
Transl Cancer Res; 2023 Sep; 12(9):2294-2307. PubMed ID: 37859742
[TBL] [Abstract][Full Text] [Related]
15. Dihydroorotate dehydrogenase regulates ferroptosis in neurons after spinal cord injury via the P53-ALOX15 signaling pathway.
Li D; Lu X; Xu G; Liu S; Gong Z; Lu F; Xia X; Jiang J; Wang H; Zou F; Ma X
CNS Neurosci Ther; 2023 Jul; 29(7):1923-1939. PubMed ID: 36942513
[TBL] [Abstract][Full Text] [Related]
16. DHODH Inhibition Exerts Synergistic Therapeutic Effect with Cisplatin to Induce Ferroptosis in Cervical Cancer through Regulating mTOR Pathway.
Jiang M; Song Y; Liu H; Jin Y; Li R; Zhu X
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672495
[TBL] [Abstract][Full Text] [Related]
17. An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy.
Huang S; Le H; Hong G; Chen G; Zhang F; Lu L; Zhang X; Qiu Y; Wang Z; Zhang Q; Ouyang G; Shen J
Acta Biomater; 2022 Aug; 148():244-257. PubMed ID: 35709941
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
19. Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells.
Wang H; Wang C; Li B; Zheng C; Liu G; Liu Z; Zhang L; Xu P
Eur J Med Chem; 2023 Jun; 254():115343. PubMed ID: 37087895
[TBL] [Abstract][Full Text] [Related]
20. Prospects for Anti-Tumor Mechanism and Potential Clinical Application Based on Glutathione Peroxidase 4 Mediated Ferroptosis.
Chen M; Shi Z; Sun Y; Ning H; Gu X; Zhang L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
